Krishna Vaddi Biography and Net Worth

CEO of Prelude Therapeutics

Kris Vaddi, Ph.D. founded Prelude Therapeutics and has served as the Chief Executive Officer and member of the Board of Directors since 2016. Prior to founding Prelude, from 2014 to 2016, Dr. Vaddi served as Chief Executive Officer of Orsenix, LLC, a clinical stage biotechnology company. Previously, he held several roles at Incyte Corporation, starting as a Founding Scientist and an Executive Director in 2002, and most recently as a Senior Advisor from 2015 to 2016. Dr. Vaddi initiated and championed JAK research programs at Incyte that led to the discovery, development, and approval of Jakafi®(ruxolotinib) for Myelofibrosis and Polycythemia Vera and Olumiant®(baricitinib) for rheumatoid arthritis. He received his BVSc in Veterinary Medicine from APAU in India and his Ph.D. in Pharmacology and Toxicology from University of Florida.

What is Krishna Vaddi's net worth?: The estimated net worth of Krishna Vaddi is at least $9.74 million as of March 25th, 2025. Dr. Vaddi owns 1,999,296 shares of Prelude Therapeutics stock worth more than $9,736,572 as of May 7th. This net worth approximation does not reflect any other investments that Dr. Vaddi may own. Learn More about Krishna Vaddi's net worth.
How do I contact Krishna Vaddi?: The corporate mailing address for Dr. Vaddi and other Prelude Therapeutics executives is , , . Prelude Therapeutics can also be reached via phone at 302-467-1280 and via email at [email protected]. Learn More on Krishna Vaddi's contact information.
Has Krishna Vaddi been buying or selling shares of Prelude Therapeutics?: Krishna Vaddi has not been actively trading shares of Prelude Therapeutics during the last quarter. Most recently, on Tuesday, March 25th, Krishna Vaddi bought 675,000 shares of Prelude Therapeutics stock. The stock was acquired at an average cost of $0.69 per share, with a total value of $465,750.00. Following the completion of the transaction, the chief executive officer now directly owns 1,999,296 shares of the company's stock, valued at $1,379,514.24. Learn More on Krishna Vaddi's trading history.
Who are Prelude Therapeutics' active insiders?: Prelude Therapeutics' insider roster includes David Bonita (Director), Andrew Combs (EVP), Bryant Lim (CFO), David Mauro (Insider), Deborah Morosini (EVP), Christopher Pierce (EVP), Brian Piper (CFO), Peggy Scherle (Insider), Krishna Vaddi (CEO), and Krishna Vaddi (CEO). Learn More on Prelude Therapeutics' active insiders.
Are insiders buying or selling shares of Prelude Therapeutics?: In the last year, Prelude Therapeutics insiders bought shares 2 times. They purchased a total of 5,630,630 shares worth more than $24,999,997.20. The most recent insider tranaction occured on April, 21st when Director David P Bonita bought 2,815,315 shares worth more than $12,499,998.60. Insiders at Prelude Therapeutics own 63.9% of the company. Learn More about insider trades at Prelude Therapeutics.
Information on this page was last updated on 4/21/2026.

Krishna Vaddi Insider Trading History at Prelude Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/25/2025	Buy	675,000	$0.69	$465,750.00	1,999,296
3/12/2025	Buy	47,500	$0.71	$33,725.00	1,214,775
12/30/2024	Buy	10,000	$1.20	$12,000.00	137,553
12/18/2024	Buy	100,000	$0.93	$93,000.00	1,167,275
5/24/2023	Buy	1,000	$5.01	$5,010.00	1,066,375
12/20/2022	Buy	19,188	$5.13	$98,434.44	120,665

Krishna Vaddi Buying and Selling Activity at Prelude Therapeutics

Prelude Therapeutics Company Overview

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Today's Range

Now: $4.87

$4.65

$4.88

50 Day Range

MA: $3.73

$2.63

$5.52

2 Week Range

Now: $4.87

$0.75

$5.54

Volume

28,008 shs

Average Volume

395,355 shs

Market Capitalization

$306.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11